Clinical Trial Update: Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) [Phase 2]

View source ↗

Summary

Phase 2 NCI MATCH subprotocol V is evaluating sunitinib for cancers with cKIT genetic alterations, including advanced and refractory lymphomas and solid tumors,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumor

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-19